Crossmark Global Holdings’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Crossmark Global Holdings’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-16,117	Closed	-$655K	–	1302
2024 Q3	$655K	Buy	+16,117	New	+$636K	0.01%	754

Crossmark Global Holdings's CALT Position: Q4 2024 in Review

Crossmark Global Holdings sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q4 2024, closing a stake of 16,117 shares — an estimated $655K sold.

Crossmark Global Holdings first reported a position in CALT in Q3 2024 and held it in 1 quarter. The position peaked at $655K in Q3 2024. 0 funds tracked by Wall St. Rank hold CALT as of Q4 2024.

Crossmark Global Holdings reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q4 2024 after selling out during the quarter.
Crossmark Global Holdings sold 16,117 Calliditas Therapeutics AB American Depositary Shares shares in Q4 2024, an estimated $655K.
Crossmark Global Holdings first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q3 2024 and held it in 1 quarter.
Crossmark Global Holdings's Calliditas Therapeutics AB American Depositary Shares position peaked at $655K in Q3 2024.
0 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q4 2024.

Based on Crossmark Global Holdings's 13F filing for Q4 2024, filed 16 Jan 2025.